AI financial tools show a 3.5% higher error rate for minorities. Learn why this matters for your investments and what SEC rules are coming.
·
·
7 min read
Pelacarsen cut Lp(a) by 80%, but lacked MACE proof. This shifts drug trials to direct clinical benefits, not just biomarkers, for heart disease. What's next
·
·
8 min read
Lp(a) drug development faces hurdles. See why new therapies like ASOs are changing cardiovascular care and what to watch for by 2026.
·
·
9 min read
New therapies are targeting Lp(a), a genetic heart risk. Learn about 80% reductions in trials, ESC guidelines, and what's next for patients.
·
·
7 min read
OEM deception in military AI creates critical cybersecurity risks. Learn why third-party AI modules threaten national security by 2026.
·
·
7 min read
Novartis's Pelacarsen drug failed Phase 3 trials. We explain why it matters for future heart disease treatments and what's next for clinical trials.
·
·
7 min read
ZN-207's setback challenges heart drug innovation. See how pharma is shifting to CRISPR and AI for future heart disease treatments.
·
·
8 min read
New Lp(a) drugs target heart disease, offering hope beyond pelacarsen. See what's coming in the 2026 race to treat millions.
·
·
8 min read
Pelacarsen's Phase 3 failure delays Lp(a) drug development until 2026. Why Novartis and Ionis's trial results matter for heart disease patients.
·
·
7 min read
Novartis halted its pelacarsen trial in 2025. Why did this promising Lp(a) drug fail, and what does it mean for future heart disease treatments?
·
·
7 min read